BOARD ALERTS:Q3 Board Pack is ready for review. // Acquisition target 'Studio Alpha' signed NDA.
NYSE: AGNC 42.50 (+1.2%)
E
EXECUTIVE.
CEO
Gross Revenue (YTD)11.2%

$14.2M

vs Target $12.8M

EBITDA Margin2.5%

24.5%

Target: 22%

Client Retention1.8%

88.2%

Target: 90%

Pipeline Value8.4%

$4.8M

Weighted Forecast

Financial Performance vs Forecast

Actual Rev
Target
OpEx

Revenue by Service Line

45%Retainer

Key Account Health Matrix

Client NameRegionAnn. RevenueHealth ScoreStatusRisk Profile
Nike GlobalNA$4.2M
GrowthLow
UnileverEMEA$2.8M
StableLow
Tesla MotorsNA$1.5M
At RiskHigh
SamsungAPAC$3.1M
GrowthLow
NovartisEMEA$0.9M
ChurnMed

Strategic Risk Register

Legal Risk

High

GDPR Compliance Audit pending for EU Division.

Owner: Legal

Talent Risk

Med

Head of Strategy role vacant > 60 days.

Owner: HR

Client Risk

Critical

Tesla contract renewal negotiation stalled.

Owner: Sales

2 Critical Risks require Board Attention.